(ALNY) Alnylam Pharmaceuticals - NASDAQ
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 37.129m USD | Total Return: -8% in 12m
Avg Turnover: 340M
Qual. Beats: 1
Rev. Trend: 94.7%
Qual. Beats: 0
Warnings
Altman Z'' 1.07 < 1.0 - financial distress zone
Below Avwap Earnings
Tailwinds
No distinct edge detected
Alnylam Pharmaceuticals is a U.S.-based biotechnology company founded in 2002 and headquartered in Cambridge, Massachusetts. It is a pioneer in RNA interference (RNAi)-based therapeutics, a drug-discovery platform recognized with the 2006 Nobel Prize in Physiology or Medicine, and operates as a fully integrated business spanning discovery, development, manufacturing, and global commercialization. The company markets several approved RNAi therapies-including ONPATTRO, AMVUTTRA, GIVLAARI, OXLUMO, and Qfitlia-and earns additional royalty revenue through its collaboration with Novartis on Leqvio, used to lower LDL cholesterol in high-risk patients.
Alnylam sustains its pipeline by reinvesting revenues into a large, diversified portfolio of clinical-stage RNAi candidates targeting rare genetic diseases, cardiometabolic conditions, infectious diseases, and central nervous system disorders. Late-stage assets include Nucresiran for ATTR amyloidosis, Zilebesiran for hypertension, and Cemdisiran for complement-mediated diseases. The company has established development and commercialization partnerships with major pharmaceutical firms including Regeneron, Roche, Sanofi, Novartis, and Ionis, which is a typical structure in the biotech sector that helps share R&D costs and expand global reach.
- Amvuttra TTR franchise revenue accelerates with label expansions
- BridgeBio Attruby competition pressures Amvuttra market share
- Zilebesiran Phase 3 hypertension data readouts could unlock massive market
| Net Income: 577.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.18 > 0.02 and ΔFCF/TA 17.00 > 1.0 |
| NWC/Revenue: 66.94% < 20% (prev 93.38%; Δ -26.44% < -1%) |
| CFO/TA 0.14 > 3% & CFO 712.9m > Net Income 577.2m |
| Net Debt (-811.7m) to EBITDA (924.5m): -0.88 < 3 |
| Current Ratio: 3.13 > 1.5 & < 3 |
| Outstanding Shares: last quarter (138.2m) vs 12m ago 6.59% < -2% |
| Gross Margin: 80.89% > 18% (prev 86.01%; Δ -5.12% > 0.5%) |
| Asset Turnover: 91.76% > 50% (prev 55.72%; Δ 36.04% > 0%) |
| Interest Coverage Ratio: 3.07 > 6 (EBIT TTM 869.7m / Interest Expense TTM 283.3m) |
| A: 0.56 (Total Current Assets 4.22b - Total Current Liabilities 1.35b) / Total Assets 5.13b |
| B: -1.27 (Retained Earnings -6.50b / Total Assets 5.13b) |
| C: 0.19 (EBIT TTM 869.7m / Avg Total Assets 4.67b) |
| D: 0.27 (Book Value of Equity 1.08b / Total Liabilities 4.05b) |
| Altman-Z'' = 1.07 = BB |
| DSRI: 1.16 (Receivables 884.0m/418.0m, Revenue 4.29b/2.35b) |
| GMI: 1.06 (GM 86.01% / 80.89%) |
| AQI: 0.67 (AQ_t 0.04 / AQ_t-1 0.06) |
| SGI: 1.83 (Revenue 4.29b / 2.35b) |
| TATA: -0.03 (NI 577.2m - CFO 712.9m) / TA 5.13b) |
| Beneish M = -2.45 (Cap -4..+1) = BBB |
As of June 24, 2026, the stock is trading at USD 288.18 with a total of 1,023,360 shares traded. Over the past week, the price has changed by +0.13%, over one month by -2.48%, over three months by -6.03% and over the past year by -7.97%.
Current recommended Stop Loss: 275.80 (which is 4.3% or 1.2 ATR below the current price).
Alnylam Pharmaceuticals has received a consensus analysts rating of 4.23. Therefore, it is recommended to buy ALNY.
- StrongBuy: 15
- Buy: 7
- Hold: 8
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 436.3 | 51.4% |
P/E Trailing = 69.8719
P/E Forward = 29.7619
P/S = 8.6609
P/B = 34.5259
P/EG = 0.4747
Revenue TTM = 4.29b USD
EBIT TTM = 869.7m USD
EBITDA TTM = 924.5m USD
Long Term Debt = 1.01b USD (from longTermDebt, last quarter)
Short Term Debt = 45.7m USD (from shortTermDebt, last quarter)
Debt = 1.54b USD (from shortLongTermDebtTotal, last quarter) + Leases 263.7m
Net Debt = -811.7m USD (calculated: Debt 1.54b - CCE 2.35b)
Enterprise Value = 36.3b USD (37.1b + Debt 1.54b - CCE 2.35b)
Interest Coverage Ratio = 3.07 (Ebit TTM 869.7m / Interest Expense TTM 283.3m)
EV/FCF = 39.38x (Enterprise Value 36.3b / FCF TTM 922.1m)
FCF Yield = 2.54% (FCF TTM 922.1m / Enterprise Value 36.3b)
FCF Margin = 21.51% (FCF TTM 922.1m / Revenue TTM 4.29b)
Net Margin = 13.46% (Net Income TTM 577.2m / Revenue TTM 4.29b)
Gross Margin = 80.89% ((Revenue TTM 4.29b - Cost of Revenue TTM 819.0m) / Revenue TTM)
Gross Margin QoQ = 81.91% (prev 75.60%)
Tobins Q-Ratio = 7.08 (Enterprise Value 36.3b / Total Assets 5.13b)
Interest Expense / Debt = 18.43% (Interest Expense 283.3m / Debt 1.54b)
Taxrate = 1.57% (9.18m / 586.4m)
NOPAT = 856.0m (EBIT 869.7m * (1 - 1.57%))
Current Ratio = 2.86 (Total Current Assets 4.22b / Total Current Liabilities 1.48b)
Debt / Equity = 1.43 (Debt 1.54b / totalStockholderEquity, last quarter 1.08b)
Debt / EBITDA = -0.88 (Net Debt -811.7m / EBITDA 924.5m)
Debt / FCF = -0.88 (Net Debt -811.7m / FCF TTM 922.1m)
Total Stockholder Equity = 587.3m (last 4 quarters mean from totalStockholderEquity)
RoA = 12.36% (Net Income 577.2m / Total Assets 5.13b)
RoE = 98.29% (Net Income TTM 577.2m / Total Stockholder Equity 587.3m)
RoCE = 54.47% (EBIT 869.7m / Capital Employed (Equity 587.3m + L.T.Debt 1.01b))
RoIC = 23.70% (NOPAT 856.0m / Invested Capital 3.61b)
WACC = 7.80% (E(37.1b)/V(38.7b) * Re(7.37%) + D(1.54b)/V(38.7b) * Rd(18.43%) * (1-Tc(0.02)))
Discount Rate = 7.37% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 91.11 | Cagr: 4.50%
[DCF] Terminal Value 77.97% ; FCFF base≈569.7m ; Y1≈653.1m ; Y5≈961.1m
[DCF] Fair Price = 114.4 (EV 14.5b - Net Debt -811.7m = Equity 15.3b / Shares 133.5m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.96 | # QB: 1
Revenue Correlation: 94.68 | Revenue CAGR: 43.10% | SUE: 0.42 | # QB: 0
EPS current Quarter (2026-06-30): EPS=2.17 | Chg30d=+4.83% | Revisions=-33% | Analysts=14
EPS next Quarter (2026-09-30): EPS=2.46 | Chg30d=+3.79% | Revisions=-60% | Analysts=14
EPS current Year (2026-12-31): EPS=9.51 | Chg30d=+1.93% | Revisions=+6% | GrowthEPS=+87.1% | GrowthRev=+51.5%
EPS next Year (2027-12-31): EPS=13.77 | Chg30d=-0.23% | Revisions=-29% | GrowthEPS=+44.8% | GrowthRev=+30.2%
[Analyst] Revisions Ratio: -60%